Categories: Technology

Artificial Intelligence Risk, Inc. and Fynancial, Inc. Awarded Best in Show at RIA Edge for Fyn, the First Agentic AI Powered Assistant for Financial Advisors

 | Source: Artificial Intelligence Risk, Inc.

Greenwich, CT, June 18, 2025 (GLOBE NEWSWIRE) — Artificial Intelligence Risk, Inc. and Fynancial, Inc. were jointly awarded Best in Show at Wealth Management EDGE 2025 in Boca Raton, FL for Fyn, an agentic AI powered assistant for financial advisors.

Fyn, launched this month in a JV between AI Risk and Fynancial simplifies day-to-day advisor workflows by combining firm data, client activity, and platform integrations into one intelligent command center. 

Artificial Intelligence Risk, Inc., a firm specializing in AI governance, risk, compliance, and cybersecurity (GRCC), partnered with Fynancial to build out the AI agents for Fyn and operate within a robust safety framework that includes permission-based access, hallucination filtering, agent testing, and role-based control over sensitive data. AI Risk has a patent pending on AI GRCC – a governance, risk, compliance and cybersecurity platform specifically for Gen AI.

Reflecting on the award, Alec Crawford, CEO and Co-Founder of Artificial Intelligence Risk Inc., notes, “I am so proud of the team effort between Artificial Intelligence Risk, Inc. and Fynancial. Winning shows not just the power of our agentic AI platform to help financial advisors, but also the necessity of having AI governance, risk, compliance, and cyber security at the heart of enterprise AI. That’s what we do.”

Learn more about Artificial Intelligence Risk Inc.

About Artificial Intelligence Risk 
Artificial Intelligence Risk (AI Risk, Inc.) is the leader in AI governance, risk, compliance, and cybersecurity (AI GRCC) software, offering the first comprehensive advanced platform for generative-AI safety, security, and regulatory compliance. Founded in 2023 by Alec Crawford, Frank Fitzgerald and Joe McMann, AI Risk’s team has decades of experience in artificial intelligence, financial services, risk management, and compliance. The company focuses on rapid (one hour) private cloud deployment and strict data confidentiality, enabling secure and regulatory-compliant use of AI and generative-AI technologies for high-risk organizations across the globe. For more information, please visit aicrisk.com

About Fynancial 
Fynancial is a mobile-first digital experience platform that redefines how advisors and clients connect. Fully white-labeled and integrated across an RIA’s existing tech stack, Fynancial enables secure messaging, real-time meeting scheduling, document sharing, and personalized push notifications, all through a firm-branded app. By centralizing communication and integrating with platforms like Orion, Tamarac, Addepar, and Black Diamond, Fynancial delivers a seamless, high-engagement experience that helps advisors scale trust, drive referrals, and modernize client service.

Contact: 

Alec Crawford, CEO 

aleccrawford@aicrisk.com 

GlobeNews Wire

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

2 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

2 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

2 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

4 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

4 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

4 hours ago